Comparison of the effect of oral progesterone and vaginal progesterone on luteal phase support

Comparison of the effect of oral progesterone and vaginal progesterone on luteal phase support using available drugs in IVF/ICSI candidates

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20211101052938N1

Enrollment

160

Registered

2021-11-14

Start date

2021-12-02

Completion date

Unknown

Last updated

2022-11-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

In vitro fertilization.

Interventions

Intervention 1: Intervention group: in this group 400 mg vaginal progesterone (Fertigest 400 mg vaginal of Aburaihan ?Pharmaceutical Co)is prescribed for luteal phase support. Intervention 2: Control

Eligibility

Sex/Gender

Female

Age

18 Years to 40 Years

Inclusion criteria

Inclusion criteria: IVF/ICSI candidate with history of infertility age between 18 to 40 years old have an informed consent to participate in the study

Exclusion criteria

Exclusion criteria: drug reaction history to one of the drugs used in this study endocrine or metabolic disorders endometriosis Azospermia of partner uterine anatomic anomaly history of 2 or more unsuccessful IVF or FET history of repetitive spontaneous abortion

Design outcomes

Primary

Measure	Time frame
Percent of successful pregnancy following in vitro fertilization. Timepoint: Evaluating the outcome of pregnancies at the end of the study. Method of measurement: Recording the successful and unsuccessful pregnancy.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactNazli Ghamari

Zanjan University of Medical Sciences

nazlighamari@zums.ac.ir+98 24 3313 0001

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026